A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

Neoplasia (United States)

Volumn 19, Issue 7, 2017, Pages 530-536

  Mediavilla Varela, Melanie ^a   Castro, Julio ^b   Chiappori, Alberto ^a   Noyes, David ^a   Hernandez, Dalia C ^c   Allard, Bertrand ^d   Stagg, John ^d,e   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NOAIN ^*  (Spain)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; CYCLIC AMP; PBF 509; PROGRAMMED DEATH 1 INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASM METASTASIS; NEOPLASMS; RECEPTOR, ADENOSINE A2A; TUMOR MICROENVIRONMENT;

EID: 85024929161     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2017.02.004     Document Type: Article

References (33)

1. Sandler, A, Gray, R, Perry, MC, Brahmer, J, Schiller, JH, Dowlati, A, Lilenbaum, R, Johnson, DH, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
2. Yao, S, Zhu, Y, Chen, L, Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12 (2013), 130–146.
3. Nguyen, LT, Ohashi, PS, Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nat Rev Immunol 15 (2014), 45–56.
4. Pardoll, DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
5. Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
6. Lee, SJ, Jang, BC, Lee, SW, Yang, YI, Suh, SI, Park, YM, Oh, S, Shin, JG, Yao, S, Chen, L, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580 (2006), 755–762.
7. Philips, GK, Atkins, M, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 27 (2015), 39–46.
8. Jin, D, Fan, J, Wang, L, Thompson, LF, Liu, A, Daniel, BJ, Shin, T, Curiel, TJ, Zhang, B, CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70 (2010), 2245–2255.
9. Stagg, J, Smyth, MJ, Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29 (2010), 5346–5358.
10. Di Paola, R, Melani, A, Esposito, E, Mazzon, E, Paterniti, I, Bramanti, P, Pedata, F, Cuzzocrea, S, Adenosine A2A receptor-selective stimulation reduces signaling pathways involved in the development of intestine ischemia and reperfusion injury. Shock 33 (2010), 541–551.
11. Ohta, A, Sitkovsky, M, Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 (2001), 916–920.
12. Zarek, PE, Huang, CT, Lutz, ER, Kowalski, J, Horton, MR, Linden, J, Drake, CG, Powell, JD, A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111 (2008), 251–259.
13. Ohta, A, Gorelik, E, Prasad, SJ, Ronchese, F, Lukashev, D, Wong, MK, Huang, X, Caldwell, S, Liu, K, Smith, P, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103 (2006), 13132–13137.
14. Young, A, Mittal, D, Stagg, J, Smyth, MJ, Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov 4 (2014), 879–888.
15. Beavis, PA, Divisekera, U, Paget, C, Chow, MT, John, LB, Devaud, C, Dwyer, K, Stagg, J, Smyth, MJ, Darcy, PK, Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 110 (2013), 14711–14716.
16. Mittal, D, Young, A, Stannard, K, Yong, M, Teng, MW, Allard, B, Stagg, J, Smyth, MJ, Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 74 (2014), 3652–3658.
17. Dungo, R, Deeks, ED, Istradefylline: first global approval. Drugs 73 (2013), 875–882.
18. Hauser, RA, Olanow, CW, Kieburtz, KD, Pourcher, E, Docu-Axelerad, A, Lew, M, Kozyolkin, O, Neale, A, Resburg, C, Meya, U, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 13 (2014), 767–776.
19. Pinna, A, Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28 (2014), 455–474.
20. ClinicalTrials.gov, Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers. Available at: https://clinicaltrials.gov/ct2/show/NCT01691924.
21. ClinicalTrials.gov, Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF −509 (80 mg, 160 mg and 240 mg) “After Multiple Oral Doses” in Healthy Volunteers. Available at: https://clinicaltrials.gov/ct2/show/NCT02111330 [Accessed June 20, 2016].
22. Leff, P, Dougall, IG, Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14 (1993), 110–112.
23. Vu, CB, Pan, D, Peng, B, Kumaravel, G, Smits, G, Jin, X, Phadke, D, Engber, T, Huang, C, Reilly, J, et al. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists. J Med Chem 48 (2005), 2009–2018.
24. Liu, X, Ory, V, Chapman, S, Yuan, H, Albanese, C, Kallakury, B, Timofeeva, OA, Nealon, C, Dakic, A, Simic, V, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180 (2012), 599–607.
25. Jenner, P, Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 14 (2005), 729–738.
26. ClinicalTrials.gov. Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC).
27. Cekic, C, Day, YJ, Sag, D, Linden, J, Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 74 (2014), 7250–7259.
28. Cekic, C, Linden, J, Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res 74 (2014), 7239–7249.
29. Muller-Haegele, S, Muller, L, Whiteside, TL, Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol 10 (2014), 897–914.
30. Beavis, PA, Milenkovski, N, Henderson, MA, John, LB, Allard, B, Loi, S, Kershaw, MH, Stagg, J, Darcy, PK, Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunol Res 3 (2015), 506–517.
31. Iannone, R, Miele, L, Maiolino, P, Pinto, A, Morello, S, Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 4 (2014), 172–181.
32. Mediavilla-Varela, M, Luddy, K, Noyes, D, Khalil, FK, Neuger, AM, Soliman, H, Antonia, SJ, Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther 14 (2013), 860–868.
33. Zhang, B, CD73: a novel target for cancer immunotherapy. Cancer Res 70 (2010), 6407–6411.